In GxP, AI Needs Two Proofs: System Qualification and Output Credibility
AI validation in GxP requires more than a single qualification exercise. When your organization deploys an AI tool to support GxP processes—for example, GMP batch record review, deviation triage, or lot disposition—regulators and auditors are increasingly likely to expect you to demonstrate two distinct types of assurance. First, that the system itself is qualified for its intended use in your environment (the same kind of evidence you’d produce for any computerized system under CSA). Second, and this is where most teams stumble, that the AI outputs are credible enough for the specific decisions they inform. These are fundamentally different questions, and answering one does not satisfy the other.
This article introduces the Xevalics Two-Track AI Assurance Framework—a practical model for building inspection-ready AI compliance in GMP environments. It draws on the FDA’s draft guidance on AI-supported regulatory decision-making [1], EMA’s draft Annex 22 guidance on AI in pharmaceutical manufacturing [2], and the EFPIA position paper on AI in GMP [3]. If you’re a QA leader, CSV/CSA practitioner, or IT-Quality partner evaluating AI tools, this framework gives you a clear starting point.
What Does AI Validation in GxP Require?
The short answer: you don’t validate AI with a single activity. You build two parallel workstreams—one for system-level assurance (is the tool reliable in your environment?) and one for output-level credibility (are the AI’s results trustworthy for a defined decision?). The distinction matters because a system can pass every qualification test and still produce outputs that aren’t credible for a specific Context of Use.
Think of it this way. Validation and assurance operate at the use level—they ask whether the system is fit for its intended use in real operations. Credibility operates at the decision level—it asks whether a specific output can be trusted for a specific decision, given the consequences of that decision being wrong.
The FDA’s draft guidance (January 2025) presents this credibility concept through a risk-based credibility assessment framework built around two risk factors: model influence (how much the AI output contributes to the decision) and decision consequence (the potential impact if that decision is wrong). The higher both factors, the more rigorous the credibility evidence should be. This is risk-based confidence—and it’s the organizing principle behind both tracks in our framework [1].
Who Needs This Framework?
This framework applies to any organization using AI to support GMP-regulated decisions. The primary audiences include QA leaders and QP/release teams responsible for disposition; digital quality, CSV, and CSA teams implementing AI-enabled workflows across eBR, MES, or LIMS platforms; and IT-Quality partners building AI decision-support tools for deviations, investigations, and batch release.
Even if your AI tool is operating strictly as decision support—with a qualified human making the final call—you still need both tracks. Human oversight reduces risk, but it does not replace evidence.
The GMP Use Case: AI-Assisted Batch Record Review and Lot Disposition
To make this concrete, consider a common emerging use case. An AI tool helps QA reviewers by flagging anomalies across electronic batch records, MES data, and LIMS results; summarizing deviations and their disposition history; and drafting a lot disposition recommendation with supporting evidence citations. A qualified human reviews the AI’s work and makes the final release decision. The AI is decision support, not an automated release mechanism.
Even in this human-in-the-loop scenario, regulators and auditors are likely to look for both system-level and output-level evidence. Here’s what each track requires.
What Is the Difference Between System Validation and Output Credibility for AI?
This is the core distinction in the Xevalics Two-Track Framework, and it maps closely to the concepts in FDA’s draft credibility assessment guidance [1] and EMA’s draft Annex 22 [2].
Track 1 — Validation / Qualification: “Is the System Fit for Intended Use?”
This is your CSA-style assurance for the computerized system in your environment. It covers the controls you’d expect for any GxP-regulated tool: intended use documentation, risk assessment (including AI-specific failure modes), data integrity controls across interfaces, security and access control with proper segregation of duties, audit trail integrity and record retention, and change control for configuration, model, prompt, and workflow updates.
The key question at this level is: Is the system reliable and controlled enough to operate in our GMP workflow? The result, when demonstrated, is that the system is assured for its intended use over time.
What auditors typically look for in Track 1 includes the intended use statement with risk assessment, including AI-specific failure modes such as hallucination, drift, and prompt sensitivity; data integrity controls at every interface point; access controls with role-based segregation; complete audit trail with retention and retrievability; change control procedures that explicitly cover model versions, prompt templates, and configuration changes; and deviation and incident handling with CAPA pathways for AI-related issues.
Track 2 — Credibility Assurance: “Can We Trust This Output for This Decision?”
This is where the AI-specific assurance challenge lives. Credibility evidence demonstrates that the AI outputs are reliable for a defined Context of Use (COU)—with acceptance criteria tied to the decision impact and risk. An AI tool might be perfectly qualified as a system but still produce outputs that aren’t credible for a high-stakes decision like lot disposition.
The key question is: Can we trust this specific output for this specific decision, given what happens if it’s wrong? The result is that the output is credible enough for the defined decision—but this credibility may not generalize to other decisions or contexts.
What “credible” typically requires includes a formal Context of Use statement defining what the AI does and doesn’t do, a decision impact analysis assessing how wrong outputs could harm product quality or patient safety, performance testing on representative historical batches and deviations with documented acceptance criteria, output traceability requiring the AI to cite underlying records and evidence under a “no evidence, no claim” policy, drift monitoring with defined triggers for reassessment, and human oversight controls including review gates, verification steps, and escalation rules calibrated to the decision’s criticality.
How Does Risk-Based Confidence Connect the Two Tracks?
The organizing principle is straightforward: the higher the consequence of a wrong decision, and the higher the AI’s influence on that decision, the stronger both tracks need to be. This is consistent with FDA’s credibility assessment concepts [1] and the broader risk-proportionate direction reflected in draft Annex 22 [2].
For a low-risk application—say, AI summarizing batch record metadata for a human reviewer who independently verifies everything—the credibility evidence can be lighter. For a high-influence application like AI-generated disposition recommendations where the human reviewer relies heavily on the AI’s analysis, you need robust performance benchmarks, comprehensive traceability, and active drift monitoring.
This scaling principle helps prevent two common mistakes: over-engineering controls for low-risk applications, which can create bottlenecks and discourage adoption, and under-engineering controls for high-risk ones, which can create unnecessary product quality and patient safety exposure.
A Practical Two-Track Control Map You Can Implement
Use this as a blueprint. Treat System Assurance and Output Credibility as parallel workstreams with shared governance—change control, documentation, and periodic review feed both.
| Workstream | Goal | Evidence Examples | Owner (Typical) |
|---|---|---|---|
| Track 1: Validation / Qualification | System is fit for intended use in GMP workflow | Risk assessment (including AI failure modes), interface/data integrity checks, access control verification, audit trail review, change control SOPs, qualification protocols | CSV/CSA – IT – QA |
| Track 2: Credibility Assurance | Outputs are trustworthy for the defined COU | COU statement, decision impact analysis, acceptance criteria, benchmark testing on historical cases, output traceability logs, drift monitoring plan, human oversight procedures | QA – Process Owner – Data/AI SME |
What Are the Most Common Pitfalls When Validating AI for GMP?
Pitfall 1: “We validated the system, so the AI outputs are fine.” This is the most dangerous assumption. System qualification confirms the tool works as configured—it does not confirm that the AI’s analytical outputs are accurate or appropriate for your specific decision context. Fix: Separate system reliability from output credibility and test the model’s performance against your COU with acceptance criteria.
Pitfall 2: No change control over prompts, templates, or model versions. A prompt change can fundamentally alter AI behavior, yet many organizations treat prompts as informal configurations rather than controlled elements. I’ve seen teams make “minor wording tweaks” to AI prompts that completely changed the system’s anomaly detection sensitivity—with no documentation and no re-testing. Fix: Put prompts, templates, and model versions under formal change control with defined re-test triggers. The draft Annex 22 consultation framework reinforces the importance of documented controls for AI models in GMP environments [2].
Pitfall 3: AI summaries with no traceability to source records. If the AI generates a disposition recommendation that cites “three deviations with no impact” but doesn’t link to the actual deviation records, there’s no way to verify the claim. Fix: Require citations and direct links to batch evidence. Enforce a “no evidence, no claim” policy.
Pitfall 4: Drift is discovered during an audit rather than through monitoring. AI model performance can degrade over time as data distributions shift, yet many organizations have no ongoing monitoring. Fix: Establish a set of “golden” benchmark cases and trend key performance metrics over time. Define drift thresholds that trigger reassessment.
Pitfall 5: Treating human oversight as a substitute for evidence. “A human reviews everything” is not a credibility strategy. If the human reviewer is rubber-stamping AI recommendations without independent verification, the oversight is performative. Fix: Define what meaningful human oversight looks like for each decision type—including required verification steps, independent checks, and documented escalation triggers.
Where Does This Framework Fit in the Evolving Regulatory Landscape?
The two-track model is intentionally aligned with the direction regulators are heading, even though formal AI-specific GMP regulations are still evolving.
The FDA’s draft guidance on AI-supported regulatory decision-making presents a credibility assessment framework that maps closely to Track 2 by emphasizing risk-based evaluation of AI model outputs relative to model influence and decision consequence [1]. EMA’s Draft Annex 22 consultation (published July 2025) addresses AI in pharmaceutical manufacturing directly and emphasizes documented intended use, formal GxP AI validation, performance monitoring, and change control for AI models—aligning with both tracks [2]. It also signals a more cautious regulatory posture for higher-variability and adaptive AI use cases, especially where model behavior may be harder to characterize and the GMP impact is significant. The EFPIA position paper on application of AI in a GMP / manufacturing environment argues that existing GMP frameworks, including Annex 11 and GAMP 5, already provide a strong base to manage AI risks when supplemented with attention to AI-specific failure modes [3].
The two-track framework gives you a way to act now—building inspection-ready evidence packages that can remain useful whether regulators formalize new requirements or continue relying on existing frameworks with AI-specific interpretive guidance.
Frequently Asked Questions
Do we need to “validate the model” the way we would with traditional CSV?
For GMP, treat it as two parallel needs: CSA-style assurance for the system and credibility evidence for the outputs in a defined Context of Use. The stronger the decision impact, the stronger the credibility evidence and controls should be. Traditional CSV concepts apply to Track 1, but Track 2 requires additional, AI-specific evidence.
What if the AI is only used for drafting and a human finalizes everything?
You still need both tracks. System controls such as records, access, audit trails, and change control are required regardless of the AI’s role. Credibility controls such as accuracy testing, evidence traceability, and monitoring are still necessary because the human reviewer’s effectiveness depends on the quality of the AI’s inputs. Human oversight reduces risk but does not eliminate the need for evidence.
How does Annex 22 affect this framework?
EMA’s draft Annex 22 reinforces the two-track approach [2]. It emphasizes documented intended use and formal validation for AI-enabled systems and adds AI-relevant expectations around performance monitoring, drift awareness, change control, and human oversight that map closely to Track 2. Organizations that build both tracks now should be better positioned as expectations continue to mature.
Does this framework apply to generative AI (e.g., LLMs) or only to traditional ML models?
Both. The framework is technology-agnostic. Generative AI introduces additional credibility challenges—particularly around hallucination risk, output variability, and traceability—which make Track 2 even more critical. In practice, draft regulatory thinking points toward greater caution, stronger human oversight, and tighter controls when generative AI is used in GMP-relevant workflows [2].
Ready to Build Your Two-Track AI Assurance Package?
If you’re implementing AI for batch review, deviations, investigations, or disposition support, Xevalics can help you build a two-track assurance package—CSA-aligned system qualification plus COU-based output credibility—that is inspection-ready and scalable.
We work with pharmaceutical, biotech, and medical device companies to design AI compliance strategies grounded in practical regulatory experience—not theoretical frameworks.
Or explore how our AI compliance advisor Cheval can help you navigate these requirements in real time.
Related Reading from Xevalics
- Agentic AI in Regulated Environments: What Quality Leaders Need to Know
- GAMP 5 Second Edition: A Risk-Based Approach to Compliant GxP Computerized Systems
- Data Integrity in the Age of AI: ALCOA+ Principles Still Apply
Selected References
- U.S. Food and Drug Administration (FDA). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance for Industry and Other Interested Parties. January 2025. FDA guidance page. ↩
- European Commission / EudraLex Volume 4 stakeholder consultation. Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and Draft Annex 22 on Artificial Intelligence. Consultation launched July 2025. Consultation page. ↩
- European Federation of Pharmaceutical Industries and Associations (EFPIA). Application of AI in a GMP / Manufacturing Environment. Position Paper. September 2024. PDF. ↩
About the Author
Ricardo Torres-Rivera, PMP is CEO and President of Xevalics Consulting LLC, a Minneapolis-based life sciences compliance firm specializing in CSV/CSA, GLP, data integrity, and project management. With over 25 years of biopharmaceutical validation experience, Ricardo advises pharmaceutical and biotech organizations on AI compliance strategy, computer system assurance, and quality system design. He serves as Chair of the SQA CVIC Steering Committee and the CVIC AI Subcommittee, is a Distinguished Speaker and Quality College Instructor for the Society of Quality Assurance (SQA), and is an active contributor to the Midwest SQA community. Xevalics is an NMSDC-certified minority-owned business.
Regulatory & Compliance Disclaimer
This article is provided for informational and educational purposes only and does not constitute regulatory guidance, legal advice, or an official interpretation of applicable laws, regulations, or guidance documents. Organizations remain solely responsible for determining regulatory applicability and compliance.
